These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34463932)

  • 1. Telitacicept: First Approval.
    Dhillon S
    Drugs; 2021 Sep; 81(14):1671-1675. PubMed ID: 34463932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telitacicept for Recalcitrant Cutaneous Manifestations of Systemic Lupus Erythematosus: A Case Report and Review of the Literature.
    Ma X; Fu X; Cui B; Lin H
    Tohoku J Exp Med; 2022 Oct; 258(3):219-223. PubMed ID: 36047131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
    Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.
    Fan Y; Gao D; Zhang Z
    Drugs Today (Barc); 2022 Jan; 58(1):23-32. PubMed ID: 35107091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telitacicept for autoimmune nephropathy.
    Cai J; Gao D; Liu D; Liu Z
    Front Immunol; 2023; 14():1169084. PubMed ID: 37342346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.
    Zeng L; Yang K; Wu Y; Yu G; Yan Y; Hao M; Song T; Li Y; Chen J; Sun L
    J Autoimmun; 2024 Sep; 148():103291. PubMed ID: 39146891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept.
    Ji L; Geng Y; Zhang X; Deng X; Song Z; Tan M; Tan Y; Qu C; Zhang Z
    MedComm (2020); 2024 Apr; 5(4):e515. PubMed ID: 38525109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
    Dillon SR; Harder B; Lewis KB; Moore MD; Liu H; Bukowski TR; Hamacher NB; Lantry MM; Maurer M; Krejsa CM; Ellsworth JL; Pederson S; Elkon KB; Wener MH; Dall'Era M; Gross JA
    Arthritis Res Ther; 2010; 12(2):R48. PubMed ID: 20302641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis.
    Yao X; Ren Y; Zhao Q; Chen X; Jiang J; Liu D; Hu P
    Eur J Pharm Sci; 2021 Apr; 159():105704. PubMed ID: 33440243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria.
    Lv J; Liu L; Hao C; Li G; Fu P; Xing G; Zheng H; Chen N; Wang C; Luo P; Xie D; Zuo L; Li R; Mao Y; Dong S; Zhang P; Zheng H; Wang Y; Qin W; Wang W; Li L; Jiao W; Fang J; Zhang H
    Kidney Int Rep; 2023 Mar; 8(3):499-506. PubMed ID: 36938094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders.
    Kaegi C; Steiner UC; Wuest B; Crowley C; Boyman O
    Front Immunol; 2020; 11():433. PubMed ID: 32265917
    [No Abstract]   [Full Text] [Related]  

  • 12. Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review.
    Fan Q; Ji H; Liu Y; Jia C; Zou L; Yang H
    Lupus; 2024 Apr; 33(4):414-419. PubMed ID: 38320748
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
    Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
    Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report.
    Huang L; Qian G; Zhang H; Li Q; Chen L; Tang X; Zhao H
    Lupus; 2024 Feb; 33(2):172-175. PubMed ID: 38081170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.
    Wu D; Li J; Xu D; Merrill JT; van Vollenhoven RF; Liu Y; Hu J; Li Y; Li F; Huang C; Wang G; Li X; Zhao J; Zhao D; Huang C; Liu H; Wei W; Shi G; Lu F; Zuo X; Bi L; Li Z; Wang X; Zhang M; Tie N; Li J; Mo H; Fang J; Bao C; Zhang F
    Ann Rheum Dis; 2024 Mar; 83(4):475-487. PubMed ID: 38129117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of TACI-Ig on rat with adjuvant arthritis.
    Wang D; Chang Y; Wu Y; Zhang L; Yan S; Xie G; Qin Q; Jin J; Wang W; Fang J; Wei W
    Clin Exp Immunol; 2011 Feb; 163(2):225-34. PubMed ID: 21155990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
    Samy E; Wax S; Huard B; Hess H; Schneider P
    Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report.
    Chen JW; Zhan JY; Liang SP; Wang XD; Lin CS; Xu Q
    Int J Rheum Dis; 2023 Jul; 26(7):1417-1421. PubMed ID: 37218552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress in the study of BLyS and APRIL on regulating T cell responses in rheumatoid arthritis].
    Chang Y; Wei W
    Yao Xue Xue Bao; 2013 Jul; 48(7):979-85. PubMed ID: 24133964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Characteristics, Safety, and Tolerability of Telitacicept, an Injectable Recombinant Human B-Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein, in Healthy Chinese Subjects.
    Xie J; Fan X; Su Y; Zhou H; Cao S; Zhu X; Zhu M; He C; Wang Y; Fan L; Ge Q; Zhu J; Liu B; Chen X; Xie Y; Ma L; Liu Y; Chen J; Wang H; Li Z
    Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1273-1283. PubMed ID: 35844038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.